The Cystic Fibrosis Foundation (CFF) has just given its sought-after Quality Care Award for 2012-2013 to The Cystic Fibrosis Center of Rutgers Robert Wood Johnson Medical School and Robert Wood Johnson University Hospital. Established back in 2008, the Foundation’s Quality Care Award served to give due recognition to cystic fibrosis (CF) centers that…
News
Lexington, Massachusetts-based Pulmatrix made an impact at the 2014 Respiratory Drug Delivery Conference being held in Fajardo, Puerto Rico. A poster from the biotechnology company presented data related to PUR0400 (fluoroquinilone Levofloxac), a preclinical drug candidate formulated using Pulmatrix’s proprietary iSPERSE™ dry powder technology. PUR0400 is a drug formulation that…
Since its founding a little over two decades ago, the AbbVie Cystic Fibrosis (CF) Scholarship has been steadfast in its mission to recognize and foster the scholastic capabilities and potential of students afflicted with CF, awarding over $2.4 million worth of scholarships. Now on its 22nd year, the biopharmaceutical-backed…
How today’s healthcare industry approaches cystic fibrosis (CF) has come a long way since the mid-1960s, when individuals diagnosed with CF rarely lived up to the age of 10. Fortunately today, thanks to fervent efforts from all over the globe, those afflicted with this genetic disorder have the chance…
Adding to the excitement of Vertex Pharmaceuticals Inc.‘s new orphan drug status of VX-661 is the announcement of the results of Vertex’s Phase 2 clinical study of…
There is some good news for cystic fibrosis patients who suffer with Chronic Burkholderia Species Infection. A Phase 3b clinical trial for Aztreonam, a therapeutic for use in CF patients with Burkholderia infections, was recently sponsored by Gilead Sciences, Inc. Gilead Sciences is a research based biopharmaceutical company engaged in…
In April 2004, the Food and Drug Administration (FDA) issued a new rule requiring makers of pancreatic enzyme products (PEPs) to get their drugs approved by April 28, 2010. Unapproved pancreatic enzyme products had been available for many years, but after that cut-off date, makers of pancreatic enzyme products were required…
Xenetic Biosciences recently announced that the drug developer’s Phase I clinical trial of its new cystic fibrosis treatment PulmoXen has yielded positive results in the treatment of the disease. The announcement comes as promising news for the 30,000 patients with CF who live in the United States, and who remain…
A major drug developer is switching gears from Hepatitis C to Cystic Fibrosis, as Vertex’s new Proof-of-Concept Study Finds VX-661 And Kalydeco (ivacaftor) CF Drug Combination Improves Lung Function in Some Patients. For those in the cystic fibrosis patient population who follow research news for hints of the next major pharmaceutical development,…
While Cystic Fibrosis news is never in short supply, often times, many clinical trials currently underway to test experimental CF therapies are underreported by the media, who instead seek to cover fundraising and human interest stories about the disease. While these types of news articles are indeed important to…
Your CF Community
Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.